Life Science News

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the 2022 Jefferies Global Healthcare Conference, June 8-10, 2022 .

Raj Mehra, Ph.D., Chairman and CEO and Michael Golembiewski , CFO, will present on Friday, June 10th at 12:00 PM ET and host 1x1 meetings.

The 2022 Jefferies Global Healthcare Conference is an annual gathering where over 500 public & private healthcare companies and 3,000 leading executives, institutional investors, private equity investors & VCs will address near-term and long-term investment opportunities and discuss the current trends driving healthcare in the U.S. and internationally.

Presentation webcast registration may be accessed here .

For questions about the conference, please email healthcareconference@jefferies.com .

About Seelos Therapeutics

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD), amyotrophic lateral sclerosis (ALS), spinocerebellar ataxia (SCA), Sanfilippo syndrome, Parkinson's disease, other psychiatric and movement disorders plus orphan diseases.

For more information, please visit our website: http://seelostherapeutics.com , the content of which is not incorporated herein by reference.

Contact Information:
Anthony Marciano
Head of Corporate Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Avenue
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com
https://seelostherapeutics.com/
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos

Mike Moyer
Managing Director
LifeSci Advisors, LLC
250 West 55th St., Suite 3401
New York, NY 10019
(617) 308-4306
mmoyer@lifesciadvisors.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/seelos-therapeutics-to-participate-in-the-2022-jefferies-global-healthcare-conference-301545553.html

SOURCE Seelos Therapeutics, Inc.

News Provided by PR Newswire via QuoteMedia

SEEL:US
Awakn Life Sciences Files Patent Cooperation Treaty  Application for the Treatment of Behavioral Addictions

Awakn Life Sciences Files Patent Cooperation Treaty Application for the Treatment of Behavioral Addictions

Successful Behavioral Addiction Study Supplied Data for Patent

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing, and commercializing therapeutics to treat addiction, announced today the filing of a Patent Cooperation Treaty (PCT) application for the treatment of behavioral addictions with ketamine and ketamine-assisted psychotherapy. The successful completion of Awakn's behavioral addictions study was announced last week and the data provided from the study was used in the patent filing. The pilot study investigated ketamine as a potential new treatment approach for Gambling Disorder, Internet Gaming Disorder, Compulsive Sexual Behavior Disorder and Binge Eating Disorder.

The PCT covers all behavioral addictions or any recognized disorder or condition with similar compulsive symptoms to those in the study. If granted, the patent claims would give Awakn exclusive rights to use ketamine and ketamine-assisted therapy for the treatment of behavioral addictions. With no effective pharmacological treatments available globally at present for behavioral addictions, the study results and the patent filing position Awakn at the forefront of the industry at a time when rates of behavioral addictions are increasing at an alarming pace and sufferers have few treatment options which deliver poor outcomes.

The promising results from the pilot study showed a reduction of symptoms for some participants, with some participants no longer meeting the criteria for a diagnosis. Some individuals also showed a reduction of the symptoms of a comorbid psychiatric condition, such as depression or anxiety. The treatment was also well tolerated with no safety concerns.

Awakn CEO, Anthony Tennyson, commented, "Today's news demonstrates our focus on researching, developing and commercializing therapeutics to treat addiction. A core part of our efforts is to continually strengthen our IP portfolio as we work to bring effective therapies to chronic addiction sufferers in desperate need. To be forging a path to find an effective treatment for such a vast unmet medical need is critical and an effort we are very proud to be a part of."

Gambling Disorder, Internet Gaming Disorder, and Binge Eating Order are all recognised in the DSM-5, which is a diagnostic tool that serves as the principal authority for psychiatric diagnoses in the US, and affect up to 450 million1, 235 million2 and 100 million3 people respectively. While Compulsive Sexual Behavior Disorder, which is included in the ICD-11, affects up to 350 million4 people. The ICD-11 was developed by the World Health Organization (WHO) and is the global standard for recording health information and causes of death. Current standard of care for all of these conditions is poor.

About Awakn Life Sciences Corp.

Awakn Life Sciences is a biotechnology company, researching, developing, and commercializing combined therapeutics to treat addiction, with a focus on Alcohol Use Disorder. Awakn's team consists of renowned research experts, world leading chemists, scientists, psychiatrists, and psychologists. Addiction is one of the biggest unmet medical needs of our time, affecting over 20% of the global population and is an industry valued at over $100bn per annum. Awakn is working to disrupt this underperforming industry by advancing the next generation of drugs and therapies to be used in combination, through preclinical research and clinical stage trials.

www.awaknlifesciences.com | Twitter | LinkedIn | Facebook

Notice Regarding Forward-Looking Information

This news release contains certain forward-looking information and forward-looking statements, as defined in applicable securities laws (collectively referred to herein as "forward-looking statements"). Forward-looking statements reflect current expectations or beliefs regarding future events or the Company's future performance. All statements other than statements of historical fact are forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "continues", "forecasts", "projects", "predicts", "intends", "anticipates", "targets" or "believes", or variations of, or the negatives of, such words and phrases or state that certain actions, events or results "may", "could", "would", "should", "might" or "will" be taken, occur or be achieved, including statements relating the business of the Company. All forward-looking statements, including those herein are qualified by this cautionary statement.

Although the Company believes that the expectations expressed in such statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the statements. There are certain factors that could cause actual results to differ materially from those in the forward-looking information. These include, but are not limited to:COVID-19; fluctuations in general macroeconomic conditions; the business plans and strategies of the Company; the ability of the Company to comply with all applicable governmental regulations in a highly regulated business; the inherent risks in investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal in some jurisdictions; changes in laws; limited operating history; reliance on management; requirements for additional financing; competition; fluctuations in securities markets; inconsistent public opinion and perception regarding the medical-use of psychedelic drugs; expectations regarding the size of the addiction market; and regulatory or political change. Readers are cautioned that the foregoing list of factors is not exhaustive of the factors that may affect forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release speak only as of the date of this news release or as of the date or dates specified in such statements.

Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking information. For more information on the Company, investors are encouraged to review the Company's public filings on SEDAR at www.sedar.com. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States. The Company's and Awakn's securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Investor Enquiries:
Anthony Tennyson, CEO, Awakn Life Sciences
anthony.tennyson@awaknlifesciences.com

Media Enquiries:
America and Canada: KCSA Strategic Communications
Anne Donohoe
Adonohoe@KCSA.com

Rest of World: ROAD Communications
Paul Jarman / Nora Popova
Awakn@roadcommunications.co.uk

Keep reading... Show less
Optimi Health

Optimi Health


Keep reading... Show less
Optimi Health

Open For Business: Optimi Completes First Grow of Psilocybin Mushrooms and Introduces Head of Cultivation

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, is pleased to announce an historical milestone in the Company's road to commercialization with the successful completion of its first batch of psilocybin cubensis and functional mushrooms.

With the vast availability of Optimi's newly acquired genetics and recent amendment to its Health Canada's Dealer's Licence, Optimi is positioned to lead the industry in the scalable cultivation of mushrooms and is ready to deliver on the Company's promise of building a future where natural psychedelic alternatives aid a wide variety of mental health conditions.

Keep reading... Show less
Nirvana Life Sciences Inc.

Nirvana Life Sciences Announces Partner Symeres Can Produce High Volume Controlled Substances

Nirvana Life Sciences Inc. (CSE: NIRV) (Nirvana or the "Company"), a western Canadian based life sciences company aimed at developing non-addictive chronic pain and relapse preventing products announces that its strategic partners Symeres are licensed to produce large quantities of controlled compounds required by Nirvana.

The company is excited to announce that strategic partner Symeres has confirmed with Nirvana Life Sciences, its ability to produce up to 1000g batches of pharmaceutical Psilocybin and Psilocin. These batches can then be utilized for sale to qualified investigators for use in research and development of such compounds as well as pre-clinical and clinical trials. Nirvana believes there will be significant demand for psychedelic compounds, as an ever growing number of clinical trials and research is taking place within the psychedelic sector. This will give Nirvana Life Sciences the ability to provide a bridge to a consistent source of pharmaceutical grade, psychedelic compounds to significantly evolve and further the global psychedelic sector.

Keep reading... Show less
Awakn Life Sciences CEO, Anthony Tennyson, Joins Dustin Robinson of Iter Investments for 'The Investor Hotseat' via Live Stream on May 26th

Awakn Life Sciences CEO, Anthony Tennyson, Joins Dustin Robinson of Iter Investments for 'The Investor Hotseat' via Live Stream on May 26th

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), is pleased to announce that the company's CEO, Anthony Tennyson, will be attending The Investor Hotseat live stream event conducted by Psychedelic Invest. He will be joined in conversation with the host Dustin Robinson, Founder of Iter Investments. The company is inviting investors to join the conversation at The Investor Hotseat which will take place on May 26th 2022 at 4:30PM EST.

Ranked by Psychedelic Invest as one of the Top 100 Most Influential people in the Psychedelics industry, Dustin Robinson is a seasoned attorney, CPA and is also the founder of Iter Investments, a psychedelic fund that invests and holds a portfolio of psychedelic companies.

Keep reading... Show less

COMPASS Pathways presents largest ever study of psilocybin therapy, at American Psychiatric Association annual meeting

Positive data from phase IIb study shows potential of COMP360 psilocybin therapy
in treatment-resistant depression

London, UK 23 May 2022 COMPASS Pathways plc (Nasdaq: CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today presented positive data from the largest randomised, controlled, double-blind study of psilocybin therapy ever completed, at the American Psychiatric Association annual meeting in New Orleans*. The study showed that a single 25mg dose of COMP360 psilocybin, in combination with psychological support, was associated with a highly statistically significant reduction in depressive symptoms after three weeks (p

Keep reading... Show less

Latest Press Releases

Related News

×